Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Immune and Inflammatory Markers May Help Assess CAR T-Cell Complication Risk

By LabMedica International staff writers
Posted on 28 Oct 2026

Cytokine release syndrome (CRS) can occur after chimeric antigen receptor (CAR) T-cell therapy in patients with autoimmune disease. More...

Identifying which patients are more likely to develop this complication remains a challenge before treatment, limiting opportunities for closer monitoring and risk assessment. A new study shows that baseline immune cell levels and inflammation are associated with CRS risk following CAR T-cell therapy.

Investigators at Universitätsklinikum Erlangen (Erlangen, Germany) and collaborating institutions evaluated biomarkers that could predict the incidence and severity of cytokine release syndrome (CRS) in patients with autoimmune diseases treated with autologous CAR T-cell therapy. The retrospective cohort study included patients from six centers in Germany and one in China and focused on immune and inflammatory markers measured before CAR T-cell administration.

The study included 108 patients with autoimmune diseases who received autologous CAR T-cell therapy between March 1, 2021, and July 1, 2025. CRS developed in 80% of patients following treatment. CRS was grade 1 in 66% of patients, grade 2 in 13%, and grade 3 in 1%.

Immune effector cell-associated neurotoxicity syndrome was also observed in three patients, representing 3% of the cohort. This included grade 1 cases in 2% of patients and grade 2 cases in 1%. Patients who developed CRS had significantly higher baseline B-cell counts, interleukin-6 (IL-6) concentrations, and C-reactive protein levels.

Multivariable logistic regression confirmed the association between CRS and both B-cell counts and IL-6 concentrations. The reported odds ratios were 1.31 for B-cell counts and 2.28 for IL-6 concentrations. The findings were published in the November issue of The Lancet Rheumatology and support biomarker-based identification of patients at increased risk for CRS, with the authors noting potential relevance for preventive treatment or more intensive monitoring before and after CAR T-cell administration.

Related Links
Universitätsklinikum Erlangen 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Drug Testing Assays
Atellica DT 250 Analyzer
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New evidence now questions whether a single stool-test cutoff should be applied uniformly across all age groups.(Photo courtesy of Paul Maguire - Adobe Stock)

Study Questions Uniform Stool-Test Cutoff Across Age Groups

Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.